3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Gastrointestinal
2
Endocrine
2
Conditions
Carcinoma, Hepatocellular
14
Colorectal Neoplasms
13
Stomach Neoplasms
12
Pancreatic Neoplasms
11
Liver Neoplasms
8
Neuroendocrine Tumors
7
Neoplasm Metastasis
6
Gastrointestinal Neoplasms
4
Esophageal Neoplasms
4
Colonic Neoplasms
4
Neoplasms
3
Digestive System Neoplasms
3
Gastrointestinal Stromal Tumors
2
Gastro-enteropancreatic neuroendocrine tumor
2
Gallbladder Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Breast Neoplasms
2
Adenocarcinoma Of Esophagus
2
Adenocarcinoma
2
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thrombocytosis
1
Stomach Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Salivary Gland Neoplasms
1
Interventions
lutetium Lu 177 dotatate
8
lanreotide
4
copper dotatate CU-64
4
Octreotide
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
pasireotide
3
Magnetic Resonance Spectroscopy
3
Lutetium-177
3
Lutetium
3
gallium Ga 68 dotatate
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Nivolumab
2
Irinotecan
2
Ga(III)-DOTATOC
2
Everolimus
2
Etoposide
2
Carboplatin
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
irinotecan sucrosofate
1
folfirinox
1
famitinib
1
cabozantinib
1
arginyllysine
1
abemaciclib
1
X-Rays
1
Sunitinib
1
Somatostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Everolimus
×
Gastrointestinal
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled